BioCryst Pharmaceuticals, Inc. (BCRX)
8.90
+0.07
(+0.79%)
USD |
NASDAQ |
May 07, 16:00
9.02
+0.12
(+1.35%)
Pre-Market: 08:31
BioCryst Pharmaceuticals Research and Development Expense (Annual) : 164.74M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| KalVista Pharmaceuticals, Inc. | 55.64M |
| Lantheus Holdings, Inc. | 177.31M |
| Revolution Medicines, Inc. | 978.68M |
| Plus Therapeutics, Inc. | 8.379M |